Steve Harr, CFO & Head, Corporate Development at Juno Therapeutics, Inc. (JUNO), sold 8,750 shares at $44.74 ($392K) on 2017-12-21, disclosed to the SEC on 2017-12-22.
Open-market sale of $392k JUNO by CFO & Head, Corporate Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $44.74 | 8,250 | $369K | 94.2% |
| 2 | $45.18 | 500 | $23K | 5.8% |
| Total | $44.77 avg | 8,750 | $392K | 100% |
| Filing → |
| JUNO | SELL | 2016-06-13 | $2.6M | — | Filing → |
| JUNO | SELL | 2016-03-04 | $225K | — | Filing → |
| JUNO | SELL | 2016-03-02 | $2.2M | — | Filing → |